The Impact of COVID-19 Pandemic Lockdown on the Incidence of New-Onset Type 1 Diabetes and Ketoacidosis Among Saudi Children

Aqeel Alaqeel1*, Fahad Aljuraibah2,3,4, Mohammed Alsuhaidani7, Mohammed Huneif6, Abdulhameed Alshehri6, Mohammad Al Dubayee2,3,4, Abdulaziz Alsheikh2, Ayman Bakkar7, Ahmed Alnahr7, Areej Taha9, Khulood Alharbi2,10, Yousef Alanazi2,11, Samia Almadhi6 and Reem Al Khalifah9

1 Department of Pediatrics, College of Medicine, Qassim University, Buraidah, Saudi Arabia, 2 Pediatric Department, King Abdullah Specialized Children’s Hospital, Riyadh, Saudi Arabia, 3 College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, 4 King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard-Health Affairs (MNGHA), Riyadh, Saudi Arabia, 5 Department of Pediatrics, College of Medicine, Najran University, Najran, Saudi Arabia, 6 Pediatric Endocrine Department, Obesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia, 7 Al Hada Armed Forces Hospital, Pediatric Department, Pediatric Endocrine Division, Taif, Saudi Arabia, 8 Diabetes and Endocrinology Center, King Fahad Central Hospital in Jizan, Jizan, Saudi Arabia, 9 Pediatric Endocrinology Division, Pediatrics Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia, 10 Department of Pediatrics, College of Medicine, Taibah University, Madinah, Saudi Arabia, 11 Department of Pediatrics, College of Medicine, Majmaah University, Majmaah, Saudi Arabia

Background: Overburdened healthcare systems during the coronavirus disease (COVID-19) pandemic led to suboptimal chronic disease management, including that of pediatric type 1 diabetes mellitus (T1DM). The pandemic also caused delayed detection of new-onset diabetes in children; this increased the risk and severity of diabetic ketoacidosis (DKA). We therefore investigated the frequency of new-onset pediatric T1DM and DKA in Saudi Arabia during the COVID-19 pandemic and compared it to the same period in 2019.

Methods: We conducted a multicenter retrospective cohort study, including patients aged 1–14 years admitted with new-onset T1DM or DKA during the COVID-19 pandemic (March–June 2020) and the same period in 2019. We assessed factors including age, sex, anthropometric measures, nationality, duration of diabetes, diabetes management, HbA1c levels, glycemic control, cause of admission, blood gas levels, etiology of DKA, DKA complications, length of hospital stay, and COVID-19 test status.

Result: During the lockdown, 106 children, compared with 154 in 2019, were admitted to 6 pediatric diabetes centers. Among the admissions, DKA was higher in 2020 than in 2019 (83% vs. 73%; \( P<0.05 \); risk ratio=1.15; 95% confidence interval, 1.04–1.26), after adjusting for age and sex. DKA frequency among new-onset T1DM and HbA1c levels at diagnosis were higher in 2020 than in 2019 (26% vs. 13.4% [\( P<=0.001 \]) and 12.1 ± 0.2 vs. 10.8 ± 0.25 [\( P<0.001 \]), respectively). Females and older patients had a higher risk of DKA.
INTRODUCTION

The prevalence of type 1 diabetes mellitus (T1DM) in Saudi Arabia is considered to be among the highest globally (1). One of the major and life-threatening complications of T1DM is diabetic ketoacidosis (DKA) as it may potentially lead to significantly higher rates of morbidity and mortality, along with impacting families and increasing the burden on healthcare systems (2, 3). Unfortunately, the incidence of DKA in Saudi Arabia remains as high as 40–70% among patients with new-onset T1DM, which is considerably high when compared with that in other countries (4, 5). This may have worsened during the coronavirus disease (COVID-19) pandemic when access to healthcare was insufficient.

Globally, the implemented lockdowns during the COVID-19 pandemic impacted access to healthcare for patients with chronic disorders including children with T1DM (6–8). Reports from the UK, Germany, the USA, Italy, China, and Spain documented an increase in the frequency and severity of DKA among children with T1DM (9–15). The government of Saudi Arabia had implemented early measures to reduce virus transmission prior to COVID-19 being declared a pandemic. However, in March 2020, after the World Health Organization declared the COVID-19 outbreak a pandemic, and owing to an increase in infected cases, Saudi Arabia imposed further preventive measures including a nationwide lockdown, banning international and national travel, closing of schools, and suspension of elective procedures and non-essential visits to hospitals (16, 17). The lockdown was lifted by end of June 2020, and ever since, other restrictions have been gradually minimized, as of January 2021 (18, 19).

The lockdown, local travel restrictions, virtual clinics instead of routine visits, suspension of non-essential hospital visits, and increased fear of acquiring COVID-19 infections from hospitals are the potential factors for delayed presentation of diagnosed and undiagnosed T1DM. In this study, we aimed to compare the frequency and severity of DKA in children with T1DM from six large pediatric diabetes centers in Saudi Arabia between March 1 and June 30 in 2019 and 2020 to examine the effect of the pandemic.

MATERIALS AND METHODS

Population and Sampling

We conducted a retrospective multicenter cohort study that included six pediatric diabetes centers in major cities of Saudi Arabia. We included patients aged 1–14 years, who were admitted with new-onset T1DM or DKA between March 1, 2020, and June 30, 2020, and compared their data to that of patients admitted in the same period of 2019. We excluded patients with pre-existing T1DM who were admitted for other reasons such as hypoglycemia, hyperglycemia without ketoacidosis, or surgical reasons. T1DM patients were identified either through electronic medical records using ICD-9 and ICD-10 codes for diabetes and insulin use during emergency room visits or inpatient admissions while some centers used their database registry to identify eligible patients. The data were collected using an electronic Google form.

The study was approved by the Institutional Review Board or the Independent Ethics Committee of each site prior to the initiation of the study. All aspects of the study were conducted in accordance with the International Council on Harmonization Good Clinical Practice principle.

Measures

We collected data on age, sex, anthropometric measures, nationality, duration of diabetes, diabetes management, latest HbA1c reports, average of the last 3 HbA1c reports, cause of admission, blood gas levels, etiology of DKA, DKA complications, length of stay in intensive care, and length of hospital stay. The diagnosis of diabetes was based on the American Diabetes Association criteria (20). T1DM was diagnosed if patients had at least one anti-pancreatic antibody positive, without features suggestive of type 2 diabetes and other forms of diabetes. The diagnosis of DKA was defined as a pH level <7.3 and/or bicarbonate level <15 mmol/L, along with ketonemia or ketonuria in the presence of hyperglycemia (blood glucose >11 mmol/L [≈200 mg/dL]) and severe DKA as pH <7.1 and/or serum bicarbonate <5 mmol/L (3).

Outcomes

The primary outcome was the frequencies of new onset T1DM and DKA during the period of March to June of 2019 and 2020. The secondary outcomes included the percentage of children admitted with severe DKA, parentage of DKA among new onset T1DM. Severe DKA was defined as a pH level less than 7.1 and/or bicarbonate level less than 5 mmol/L.

Statistical Analysis

We presented dichotomous data as frequencies (n) and proportions (%) and continuous data as mean ± standard error of the mean (SEM) for normally distributed data. We compared the frequencies of T1DM, DKA, and severe DKA observed during the aforementioned periods using the χ² test, and the data were adjusted using a generalized linear model for age and sex. We reported the effect estimate with risk ratio (RR) with 95% confidence intervals. Data analysis was performed using Stata/SE 16.0 for Mac.
RESULTS

A total of 260 children with T1DM were admitted to six pediatric diabetes centers in March–June 2019 and 2020 periods, of whom 154 children were admitted during 2019, and 106 children were admitted in 2020. Overall, 200 (76.9%) children were admitted due to DKA, 112 of 154 patients (72.7%) in 2019 and 88 of 106 patients (83%) in 2020. Whereas overall admissions with new-onset T1DM was 98 (37.7%) in 2019 and 2020 (37% vs 38.7% respectively). The proportion of DKA among new-onset T1DM was significantly higher in 2020 (26%) than in 2019 (13.4%) [\(P<0.001\)] (Table 1).

The mean age of the children was 9.8 ± 0.2 years, 120 (46.2%) were male, and 240 (95.4%) were Saudi Arabian (Table 2).

Although the mean body-mass index (BMI) and BMI standard deviation score (SDS) were within the normal range, the study population showed higher BMI and BMI SDS in 2020, with a mean BMI z-score difference of −0.47 ± 0.28. Among 162 (62.3%) children with known T1DM, the mean diabetes duration was 4.8 ± 0.8 years. The mean HbA1c level was higher in 2020 than in 2019, with a mean difference of −0.7 ± 0.3% (\(P=0.13\)). HbA1c levels at diagnosis were significantly higher in 2020 than in 2019 (12.1 ± 0.2 vs. 10.8 ± 0.2.5) [\(P<0.001\)]. In children with established T1DM, most used multiple daily injections (91.9%), followed by insulin pump (6.5%), and two daily injections (4.9%). One child was reported to have developed cerebral edema in 2020, while 15 had developed acute kidney injury in 2019, and one in 2020 and no mortality secondary to DKA in both years.

The frequency of admission for new-onset T1DM was similar in both years. In contrast, admission due to DKA incidence was higher among newly diagnosed T1DM in 2020 (unadjusted RR=2.1; 95% CI, 1.3, 3.6) than in 2019, and (RR= 1.15; 95CI 1.04, 1.26) after adjusting for age and sex (Table 3). Females and older children had a higher risk of developing DKA and severe DKA. The frequency of severe DKA was similar in both years, after adjusting for age and sex. In 2020, two children who were diagnosed with severe DKA tested positive for COVID-19.

Risk factors leading to DKA among established cases include insulin omission (73%), infection (16%), insulin pump failure (1.2%), fasting (0.6%), improper insulin injection technique (0.6%), and other causes (0.6%).

DISCUSSION

To the best of our knowledge, this is the first multicenter study conducted in Saudi Arabia and the Middle East that compared the frequency of DKA during the COVID-19 pandemic to the same period in the previous year. Our study found a remarkable increase of 11% in DKA frequency among children with T1DM during the lockdown period. However, after adjusting for age and sex, there was no difference observed in DKA severity.

Interestingly, despite a noticeable decrease in the frequency of new-onset T1DM in children, a significant increase was found in those children presenting with DKA, compared with those in 2019. A German study found increased incidence and severity of DKA during the pandemic on March 13, 2020, through May 13 compared to the same period of 2019 and 2018; however, the incidence of new-onset T1DM diagnosis remained the same (11).

On the other hand, another study conducted in Italy between February 20 and April 14 in 2019 and 2020 found no difference in DKA incidence and new-onset T1DM diagnosis; however, an

| TABLE 1 | DKA and severe DKA from March to June 2020, during the COVID-19 pandemic, compared with the same period in 2019. |

| Overall N = 260 | 2019 N = 154 | 2020 N = 106 | P-value |
|-----------------|-------------|-------------|---------|
| Overall Known T1DM | 162(62.3) | 97(62.9) | 65(61.3) | 0.8 |
| New-onset T1DM | 98 (37.7) | 57 (37.0) | 41 (38.7) | 0.70 |
| DKA* Overall | 200 (76.9) | 112 (72.7) | 88 (83.02) | 0.05 |
| New-onset | 35 (36.5) | 15 (13.4) | 23 (26) | <0.001 |
| Known T1DM | 165(82.5) | 97(86.6) | 65(73.8) | 0.89 |
| Severe DKA* Overall | 47 (18.1) | 24 (15.6) | 23 (21.7) | 0.20 |
| New-onset | 11(23.4) | 4(16.6) | 7(30.4) | 0.13 |
| Known T1DM | 36 (76.6) | 20(83.3) | 16(69.5) | 0.60 |

| TABLE 2 | Baseline characteristics. |

| Overall N = 260 | 2019 N = 154 | 2020 N = 106 | P-value |
|-----------------|-------------|-------------|---------|
| Age, years | 9.8 (0.2) | 9.7 (0.24) | 10.0 (0.3) | 0.2 |
| Sex, male* | 120 (46.2) | 69 (44.8) | 51 (48.1) | 0.6 |
| Diabetes duration | 4.8 (0.8) | 5.1 (1.3) | 4.4 (0.3) | 0.6 |
| BMI, z-score | −0.66 (0.1) | −0.85 (0.17) | −0.39 (0.22) | 0.05 |
| HbA1c, % | 11.6 (1.1) | 11.3 (0.2) | 12.1 (0.2) | 0.05 |
| HbA1c% among new-onset | 11.5 (2.2) | 10.87 (2.5) | 12.14 (2.1) | <0.001 |
| HbA1c% among known T1DM | 11.70 (1.77) | 11.57 (1.8) | 12.0 (1.6) | 0.13 |
| Average of last 3 HbA1c, % | 10.9 (0.2) | 10.9 (0.2) | 10.9 (0.2) | 0.5 |
| PICU length of stay, days | 0.55 (0.04) | 0.5 (0.1) | 0.6 (0.1) | 0.08 |
| Hospital length of stay, days | 2.88 (0.1) | 2.9 (0.1) | 2.9 (0.2) | 0.5 |

Values are mean ± SEM unless indicated.

*N (%).
TABLE 3 | Adjusted risk ratio of DKA and severe DKA from March to June 2020, during the COVID-19 pandemic, compared with the same period in 2019.

|                  | DKA                  |                          | Severe DKA              |                          |
|------------------|----------------------|--------------------------|-------------------------|--------------------------|
|                  | Risk ratio | 95% CI | P-value | Risk ratio | 95% CI | P-value |
| Visit period, 2020\(^{a}\) | 1.15 | 1.04 | 1.26 | 0.01 | 1.37 | 0.83 | 2.25 | 0.22 |
| Age, years\(^{b}\) | 1.05 | 1.03 | 1.07 | 0.00 | 1.15 | 1.04 | 1.27 | 0.01 |
| Sex, male\(^{c}\) | 0.76 | 0.68 | 0.85 | 0.00 | 0.56 | 0.32 | 0.97 | 0.04 |
| Constant         | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.22 |

\(^{a}\)Adjusted for current age and sex.  
\(^{b}\)Adjusted for visit period and sex.  
\(^{c}\)Adjusted for current age and visit period.

An increase in DKA severity was observed (10). A survey from 88 diabetes centers in the UK between March 1, 2020, and June 30, 2020, showed an increase in the incidence and severity of DKA at diagnosis, and about 20% of the centers have attributed this to delayed presentation, while the incidence of new-onset T1DM diagnosis remained the same (12).

Another interesting finding in our data was higher HbA1c during the pandemic among new-onset T1DM with or without DKA, which could be linked to delayed presentation. This finding has not been reported in previous studies, but UK multicenter study reported HbA1c in the pandemic with no comparison (14).

The possible causes of delayed presentation and increased DKA are likely to be similar to those reported in other countries, such as the focus of frontline healthcare workers on COVID-19-related clinical manifestations. In addition, parents avoided seeking medical care when children had milder symptoms with the concern of contracting COVID-19 at the hospital and owing to difficulties in accessing healthcare services due to the lockdown (6, 9).

Despite the relatively short period of lockdown, unfortunately, the BMI of children was found to be significantly higher in 2020 than in 2019. This finding was not reported in other T1DM cohorts investigated during the same period. However, studies on healthy children reported lower physical activity and increased screen time, which are considered major factors leading to childhood obesity (21).

Based on our data and those of other groups, we emphasize the recommendation of Elbarbary et al. that dissemination of awareness regarding T1DM symptoms in the public should be continued during a pandemic (9). Furthermore, telemedicine technology has become an effective tool during this pandemic to deliver care for known and new-onset diabetic patients. Thus, in such scenarios in the future, technology and telemedicine should be used to fill the gaps when the healthcare system is overburdened (6–9, 22).

There is a paucity of data regarding the severity of COVID-19 among children with T1DM (13). While adults with diabetes who contracted COVID-19 showed a severe disease course and poor outcome, studies in children with diabetes have demonstrated a milder course and better outcome (10, 22–24). Beliard et al. showed that DKA presentation among children with T1DM who were diagnosed with COVID-19 was not significantly different from those who were not (15). In the present study, COVID-19 cases among admitted patients were rare (2/106 patients). However, both patients had severe DKA with no complications related to COVID-19. Our findings are consistent with studies that showed a low prevalence of COVID-19 among children with diabetes (25).

Our study, however, has some limitations, the major one being that not all pediatric diabetes centers in Saudi Arabia were included; hence, we were unable to present region-adjusted incidence.

We have learned from our data as well as the previous studies that the pandemic has significantly impacted children with T1DM. The pandemic has caused a delay in the diagnosis of diabetes, which markedly increased DKA frequency and severity. This data emphasizes that healthcare access to diagnosed and undiagnosed children with diabetes should continue in the standard level of care during pandemics, in addition to the need for continuing awareness about T1DM to the public and among frontline healthcare practitioners.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

AAla, MA, RA, FA, and MD designed the research study. MH, AAls, AAls, AB, KA, YA, SA, and AT collected the data. AAla and RA analyzed the data. AAla, MA, RA, and FA wrote the first draft. All authors participated in the final draft. AAla and RA take final responsibility for this article. All authors contributed to the article and approved the submitted version.

FUNDING

The researchers would like to thank the Deanship of Scientific Research, Qassim University, for funding the publication of this project.

ACKNOWLEDGMENTS

The authors acknowledge all pediatric diabetes centers who participated in this study.
REFERENCES

1. International Diabetes Federation, IDF. Atlas_8e_ppt_2018. Eighthed. Available at: http://diabetesatlas.org/resources/2017-atlas.html (Accessed 01 21, 2021).

2. Maahs DM, Hermann JM, Holman N, Foster NC, Kapellen TM, Allgrove J, et al. Rates of diabetic ketoacidosis: International comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care (2015) 38(10):1876–82. doi: 10.2337/dc15-0780

3. Wolfsdorf JL, Glaser N, Agus M, Fritsch A, Hanas R, Rewers R, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes (2018) 19(suppl 27):153–77. doi: 10.1111/pedi.12701

4. Cherubini V, Grimsman JM, Akesson K, Birkebak NH, Cinek O, Dové K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between: 2006 and 2016: results from 13 countries in three continents. Diabetologia (2020) 63:1530–41. doi: 10.1007/s00125-020-05152-1

5. Alaqeel AA. Pediatric diabetes in Saudi Arabia: Challenges and potential solutions. A review article. Int J Pediatr Adolesc Med (2019) 6(4):125–30. doi: 10.1016/j.ijpam.2019.05.008

6. Al-Sofiani ME, Alyusuf EY, Alharthi S, Algwaizah AM, Al-Khalifah R, Alfaaida A. Rapid implementation of a diabetes telemedicine clinic during the coronavirus Disease 2019 outbreak: Our protocol, experience, and satisfaction reports in Saudi Arabia. J Diabetes Science and Technology (2020) 14(6):1391–7. doi: 10.1177/1932296820947094

7. Flaherty GT, Hession P, Liew CH, Lim BCW, Leong TK, Lim V, et al. COVID-19 in adult patients with pre-existing chronic cardiac, respiratory, or metabolic disease: a critical literature review with clinical recommendations. Trop Diseases Travel Med Vaccines (2020) 6. doi: 10.1186/s40794-020-00118-y

8. Extance A. Covid-19 and long term conditions: What if you have cancer, diabetes, or chronic kidney disease? BMJ (2020) 368:m1174. doi: 10.1136/bmj.m1174

9. Elbarbary NS, Santos TJD, Beaufort CD, Agwu JC, Calliari LE, Scaramuzza AE. COVID-19 outbreak and pediatric diabetes: perceptions of health care professionals worldwide. Pediatr Diabetes (2020). doi: 10.1111/pedi.13084

10. Rabbone I, Schiaffini R, Cherubini V, Maifei C, Scaramuzza A, et al. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care (2020) 43(11):2870–2. doi: 10.2337/dc20-1321

11. Kamrath C, Mönkenmoller K, Biester T, Rohrer TR, Warmcke K, Hammersen J, et al. Ketoacidosis in children and adolescents with newly diagnosed Type 1 diabetes during the COVID-19 pandemic in Germany. JAMA (2020) 324(8):801–4. doi: 10.1001/jama.2020.13445

12. Ng SM, Woodger K, Regan F, Soni A, Wright N, Agwu JC, et al. Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: A National UK survey. BMJ Pediatr Open (2020) 4. doi: 10.1136/bmjpo-2020-000884

13. DiMeglio LA, Albanese-O’Neill A, Munoz CE, Maahs D. COVID-19 and children with diabetes updates, unknowns, and next steps: first, do no extrapolation. Diabetes Care (2020) 43(11):2631–4. doi: 10.2337/dc20-0044

14. Unsworth R, Wallace S, Oliver NS, Yeung S, Kishirsagar A, Naidu H, et al. New-onset Type 1 diabetes in children during COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care (2020) 43(11):e170–1. doi: 10.2337/dc20-1551

15. Beliardi K, Ebekozien O, Demeterco-Berggren C, Alonso GT, Gallagher MP, Clements M, et al. Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID-19 data from a multi-site surveillance registry. J Diabetes (2020). doi: 10.1111/1753-0407.13141

16. Moe SA. COVID-19 pandemic: Saudi Arabia’s role at national and international levels. J Diabetes Sci Technol (2020) 14(4):758–9. doi: 10.1177/1932296820930068

17. Available at: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic (Accessed 01 21, 2021).

18. Ban On umrah, visit, int flights to continue [internet]. The official Saudi Press Agency an approval issued to fully lift the curfew from 06 am on Sunday. Available at: https://www.spa.gov.sa/viewfullstory.php?lang=en&newsid=2100088 (Accessed 2020 Jul 16).

19. Magliah SF, Zarif HA, Alhuthabi A, Sabban MF. Managing Type 1 Diabetes among Saudi adults on insulin pump therapy during the COVID-19 lockdown. Diabetes Metab Syndr (2020) 15(1):63–8. doi: 10.1016/j.dsx.2020.12.013

20. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in Diabetes—2020. Diabetes Care (2020) 43(Suppl 1):514–31. doi: 10.2337/dc20-S002

21. Dunton GF, Do B, Wang SD. Early effects of the COVID-19 pandemic on physical activity and sedentary behavior in children living in the U.S. BMC Public Health (2020) 20(1):1351. doi: 10.1186/s12889-020-09429-3

22. Predieri B, Leo F, Candia F, Lucaccioni L, Maddo SF, Pugliese M, et al. Glycemic Control Improvement in Italian Children and Adolescents With Type 1 Diabetes Followed Through Telemedicine During Lockdown Due to the COVID-19 Pandemic. Front Endocrinol (2020) 11:595735. doi: 10.3389/fendo.2020.595735

23. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS, et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 Diabetes. Diabetes Care (2020) dc202260. doi: 10.2337/db20-0041

24. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol (2020) 8(10):813–22. doi: 10.1016/S2213-8587(20)30272-2

25. Cardona-Hernandez R, Cherubini V, Iafusco D, Schiaffini R, Luo X, Maahs DM. Children and youth with diabetes are not at increased risk for hospitalization due to COVID-19. Pediatr Diabetes (2021) 22(2):202–6. doi: 10.1111/pedi.13158

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Alaqeel, Alsaedi, Bakkar, Alsahani, Hanifej, Alsabhe, Alnasser, Bakkar, Alnabi, Alhamrani, Alnadi, and Khalifas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.